Finding New Targets for Trastuzumab Resistance in Breast Cancer
Author Information
Author(s): Sahin Özgür, Fröhlich Holger, Löbke Christian, Korf Ulrike, Burmester Sara, Majety Meher, Mattern Jens, Schupp Ingo, Chaouiya Claudine, Thieffry Denis, Poustka Annemarie, Wiemann Stefan, Beissbarth Tim, Arlt Dorit
Primary Institution: German Cancer Research Center
Hypothesis
Can we identify novel therapeutic targets to overcome de novo trastuzumab resistance in breast cancer?
Conclusion
The study identified c-MYC as a potential target for treating trastuzumab resistant breast cancer, while combinatorial targeting of ERBB receptors was not effective.
Supporting Evidence
- Combinatorial targeting of ERBB2 and EGFR did not affect the response to trastuzumab in resistant cells.
- c-MYC perturbation affected both trastuzumab sensitive and resistant cells.
- Knockdowns of CDK4, Cyclin D1, and Cyclin E1 significantly reduced pRB phosphorylation.
Takeaway
Researchers looked for new ways to treat breast cancer that doesn't respond to a common drug called trastuzumab, and they found that a protein called c-MYC might help.
Methodology
The study combined computational simulations, experimental testing of simulation results, and reverse engineering of a protein interaction network.
Limitations
The model may not account for all interactions and could miss some regulatory effects.
Statistical Information
Statistical Significance
p<0.05
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website